Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings harvesting first crop in Chile

Joint venture company DayaCann is currently harvesting in Chile.
AusCann Group Holdings harvesting first crop in Chile
The stock has quadrupled since listing in February now trading at $0.825

AusCann Group Holdings (ASX:AC8) is in the process of harvesting its first medical cannabis crop located in Chile.

The crop was planted by the DayaCann joint venture, of which AusCann holds 50:50 with Fundacion Daya.

The large open greenhouse grown plants include various strains that have been selected for specific medical usage.

An estimated 300 kilograms of dried cannabis product from the harvest will be sent to a certified manufacturing facility for processing into medicinal cannabis formulations.

Elaine Darby, managing director, commented: “We’re delighted with the harvest of our first crop with our partner Fundacion Daya and we’re confident we have selected the strongest and most appropriate strains for effective medicine formulations and further cultivation in the next harvest.”


Next steps and local market opportunity

Of the strains harvested, four have been selected as superior strains that have been clonally selected for future crops.

Pending successful clinical trials in Chile, these formulations will be registered through the Chilean National Institute of Public Health and made available for sale to Chilean patients and export markets.

South America represents a burgeoning region for medicinal cannabis with Argentina recently giving legislative approval to legalise the use of cannabis oil and other cannabis derivatives for medicinal purposes.

The Health Ministry in Argentina have also established a medical cannabis research program to provide access for patients.

DayaCann is optimally positioned in Argentina’s neighbouring country Chile to become a supplier of clinically validated medical cannabis products to Argentinian patients.

AusCann is also looking at leveraging this knowledge gained from Chile into the Australian market.


Background

Medical cannabis company, AusCann, commenced trading on the ASX in February after it raised the maximum $5 million under its prospectus offering.

AusCann intends to establish a growing facility in Australia to eventually supply Australian patients with Australian grown and manufactured medicines.

However, until domestic approvals are received, AusCann’s medicinal products will be imported from its globally recognised partners.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use